Purpose-Plexiform neurofibromas (pNF) are pathognomonic nerve and soft tissue tumors of neurofibromatosis type I (NF1), which are highly resistant to conventional chemotherapy and associated with significant morbidity/mortality. Disruption of aberrant SCF/c-Kit signaling emanating from the pNF microenvironment induced the first ever objective therapeutic responses in a recent phase 2 trial. Sunitinib malate is a potent, highly selective RTK inhibitor with activity against c-Kit, PDGFR, and VEGFR, which have also been implicated in the pathogenesis of these lesions. Here, we evaluate the efficacy of sunitinib malate in a preclinical Krox20;Nf1 flox/− pNF murine model. Experimental Design-Proliferation, β-hexosaminidase release (degranulation), and Erk1/2 phosphorylation were assessed in sunitinib treated Nf1 +/− mast cells and fibroblasts, respectively. Krox20;Nf1 flox/− mice with established pNF were treated sunitinib or PBS-vehicle control for a duration of 12 weeks. pNF metabolic activity was monitored by serial [ 18 F]DG-PET/CT imaging. 
Introduction
Neurofibromatosis type I (NF1) is an autosomal dominant genetic disorder that affects approximately 1 in 3,500 individuals worldwide [1] . A hallmark feature of NF1 is the development of plexiform neurofibromas, which arise during early life from cranial and large proximal peripheral nerve sheaths. Plexiform neurofibromas have been found to affect 25-40% of children diagnosed with NF1 [2, 3] . Although these tumors are considered benign, plexiform neurofibromas can cause severe disfigurement, disability, and even mortality from infiltration and compression of vital structures or from malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs), which can occur in up to 10% of cases [4] . Surgical excision is the current standard of therapy for plexiform neurofibromas, however this can be technically challenging due to the vascularity and the infiltrative nature of these tumors resulting in a high rate of local recurrence as observed in two large institutional studies [5, 6] . In many cases, the failure of standard therapeutic modalities have left patients, clinicians, and the research community searching for more effective treatment options.
The indolent growth characteristics of plexiform neurofibromas render them highly resistant to conventional cytotoxic chemotherapies. The potential for inducing malignant transformation to MPNSTs is another significant concern limiting the use of traditional DNA damaging agents in the treatment of these lesions. Thus, the development of targeted molecular therapies with the potential to induce growth arrest and/or regression of these slow-growing tumors represents a significant area of clinical morbidity.
NF1 is caused by germline mutations in the NF1 tumor suppressor gene, which encodes the protein neurofibromin, a p21ras (Ras) guanine triphosphate (GTP)-activating protein (GAP) that regulates Ras activation states by accelerating the hydrolysis of active Ras-GTP to inactive Ras-GDP [7] [8] [9] [10] [11] [12] . Ras-GTP recruits the serine-threonine kinase Raf-1 to the plasma membrane which then activates a series of downstream effectors such as Erk1/2 (p42/p44 MAPK) [13, 14] that drive cell proliferation, differentiation, and survival in response to extracellular stimuli. Attempts to directly target Ras itself, however, have proven difficult, primarily due to its complex post-translational modification/activation. Given these limitations, it is necessary to test experimental therapeutics that inhibit RTKs that activate Ras in multiple cell types including Schwann cells in pNFs.
Sunitinib malate is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib exhibits several key characteristics that make it an exceptional candidate for the treatment of NF1-related plexiform neurofibromas. Firstly, its biochemical properties include a reported IC50 for cKit between 1 and 10nM, which is a known RTK critical for pNF progression [15] . Secondly, sunitinib also inhibits two additional RTKs that are activated in multiple cell types within the pNF microenvironment, including: platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) [16, 17] . Targeting these two RTKs in other human cancers with similar molecular aberrations to pNF has shown some efficacy in both animal models and early human clinical trials [18, 19] . Data from previous studies demonstrates that sunitinib inhibits PDGFR and VEGFR with IC50s in the nanomolar range [20] . Finally, the safety profile and pharmacokinetics of sunitinib are established in pediatric patients through a phase I clinical trial under the direction of the Children's Oncology Group [21] .
In this study, we first demonstrated that sunitinib inhibits gain-in-functions within principle cellular constituents of the pNF microenvironment including Nf1 +/− mast cells and fibroblasts, driven by hyperactive, Ras-dependent SCF and PDGF signaling. Further, we provide evidence that sunitinib malate induces growth arrest and regression of pNF in Krox20;Nf1 flox/− mice validating broad inhibition of multiple RTKs as a potential therapy for NF1 patients with pNF.
Materials and Methods

Animals
The genetically engineered Krox20;Nf1 flox/− mice have been previously described [22] .
Animal care and experiments were conducted according to the guidelines established by the Indiana University Animal Care and Use Committee (IACUC). Progeny from these crosses were genotyped by polymerase chain reaction (PCR) as previously described [22] .
In vivo experimental design and mouse data
Cohorts of age and sex-matched Krox20;Nf1 flox/− mice were generated for drug treatment trials as described above. The metabolic activity of plexiform neurofibromas was assessed by fluorodeoxyglucose ([ 18 F] FDG) PET/CT imaging at baseline prior to treatment, 6 weeks, and 12 weeks of therapy as described in detail below. The experimental cohort consisted of 17 animals which were administered sunitinib malate 60 mg/kg/day by oral gavage. The placebo control group consisted of 9 mice that were administered the vehicle, phosphate buffered saline (PBS) by daily gavage. Treatment was initiated in 12-to 13-months of age. Daily weights were obtained with doses of drug and saline adjusted accordingly. Mice were treated for a duration of 12 weeks.
Dissection of Dorsal Root Ganglia and Measurement of Tumor Size
Immediately postmortem, mice were perfused and fixed in 4% paraformaldehyde. The dorsal root ganglia and peripheral nerves were dissected microscopically. Tumor volume was derived by the formula approximating the volume for a spheroid = (0.52 × (width) 2 × length), as measured by calipers in the largest possible dimension according to our previously established methodology [23] .
Histological Analysis
Paraffin sections were stained with hematoxylin and eosin (H&E), Masson trichrome, and toluidine blue to examine the tumor histomorphology as described previously [22] . Apoptosis was quantified histologically using TUNEL staining [24] .
PET Imaging Analysis
Serial [ 18 F]DG-PET/CT imaging was employed to identify and profile the metabolic activity of plexiform neurofibromas at baseline and in response to treatment. CT images were used to place a standardized volume of interest (VOI) template over regions lateral to the spinal cord for quantification of FDG uptake. Registered and overlaid CT image data were subsequently used to map the course of the spinal cord in relation to specific anatomical landmarks identified within the vertebral column from the first lumbar (L1) to first sacral (S1) spinal levels. Three circular regions-of-interest (ROIs) were then placed at interpolated points corresponding to the spinal cord and bilateral dorsal root ganglia (DGRs). The circular ROIs then were combined to create VOIs for the spinal cord and bilateral DRGs. FDG images were acquired 45 min following injection of 0.5-1.0 mCi of FDG into the tail vein. Animals were anesthetized with isoflurane at 40 min post injection to immobilize prior to imaging [23] .
Fibroblast and mast cell proliferation
Primary bone marrow derived mast cells and fibroblasts were cultured from Nf1 +/− mice as previously described [25, 26] . [ 3 H]Thymidine incorporation assays were performed to evaluate fibroblast and mast cell proliferation [27] . Briefly, cells were plated at a concentration of 4 × 10 3 cells/well in 96-well dishes in 200 mL of DMEM supplemented with 1% glutamine and 10% fetal calf serum (FCS), in a 37ºC, 5% CO 2 humidified incubator. Culture media was then switched to serum-free DMEM, and the cells were then cultured for 24-72 hrs. Tritiated thymidine ([ 3 H], PerkinElmer Life and Analytical Sciences, Boston, MA, USA) was added to cultures 6 hours prior to harvest on glass fiber filters (Packard Instrument Co.) and β-emission was measured.
β-Hexosaminidase Release Assay
Mast cell degranulation was evaluated by the β-hexosaminidase release assay [28] . In brief, bone marrow derived mast cells (BMMCs) were sensitized at 1 × 10 6 /mL in the presence or absence of sunitinib in complete RPMI 1640 supplemented with 1.5 µg/ml antidinitrophenyl (DNP) IgE (clone SPE-7, Sigma-Aldrich) for 2 hours at 37°C in 5% CO 2 . Cells were then washed once in Tyrode's buffer (130 mmol/L NaCl, 10 mmol/L HEPES, 1 mmol/L MgCl 2 , 5 mmol/L KCl, 1.4 mmol/L CaCl 2 , 5.6 mmol/L glucose, and 0.05% bovine serum albumin, pH 7.4) and resuspended at 2 × 10 6 /mL in Tyrode's buffer. Cells were then stimulated with recombinant murine SCF (10 ng/mL, PeproTech) for 5 minutes at 37°C. After the cells were spun down, 30 µL of supernatant was transferred to a 96-well flat-bottom plate. Then 30 µL of 1 mmol/L p-nitrophenyl-N-acetyl-D-glucosamide was added to each supernatant and mixed before incubation for 1 hour at 37°C. The reaction was terminated by the addition of 200 µL of 0.1 M Na 2 CO 3 -NaHCO 3 buffer, and optical density was read on a plate reader at a wavelength of 405 nm.
Western Blot Analysis
Western blot was performed to detect the phosphorylation of Erk1/2 following stimulation and sunitinib treatment [25, 28] .
Statistical Methods
Comparison of the mean tumor volume, differences in cellularity, and number of apoptotic cells between sunitinib-treated versus placebo-treated groups was performed using Student's t test or analysis of variance (ANOVA) with appropriate post-hoc correction. P values less than 0.05 were considered significant. Statistical analyses were performed with Prism 5.0 software (GraphPad, La Jolla, CA).
Results
Sunitinib inhibits multiple cellular functions, and biochemical activation of Erk1/2 in Nf1 +/− fibroblasts and mast cells
We first tested whether sunitinib malate inhibits the proliferation of two key constituents of the pNF microenvironment, Nf1 heterozygous mast cells and fibroblasts. Baseline [ 3 H]thymidine incorporation in unstimulated murine Nf1 +/− fibroblasts was measured, followed by stimulation with PDGF (50 ng/mL) for 5 minutes in the presence of varying concentrations of sunitinib to generate a dose response curve ( Figure 1A ). At 100 nM of sunitinib, Nf1 +/− fibroblast thymidine incorporation was reduced to basal levels, concordant with previously published results in NIH-3T3 cells [15] . We also observed similar results when we tested the ability of sunitinib to inhibit the proliferation of SCF-stimulated Nf1 +/− mast cells ( Figure 1B) . We next examined the effects of sunitinib on Nf1 +/− mast cell degranulation in response to SCF stimulation and found that sunitinib significantly reduced β-hexosaminidase release in a dose dependent fashion (p=0.02) ( Figure 1C ).
Sunitinib is a potent inhibitor of multiple RTKs including c-kit, VEGF, and PDGF. We tested the efficacy of sunitinib in inhibiting the biochemical activation of the Ras-MAPK signaling cascade, which drives gain-in-functions of multiple NF1(Nf1) haploinsufficient cell types. Nf1 +/− fibroblasts were stimulated with PDGF (50 ng/mL) for 5 minutes in the presence or absence of sunitinib (100 nM). SCF and PDGF stimulation induced a robust increase in Erk1/2 phosphorylation in Nf1 +/− mast cells ( Figure 1D ) and fibroblasts ( Figure 1E ), respectively which was markedly attenuated in sunitinib treated cells despite growth factor stimulation.
Reduced plexiform neurofibroma number and residual tumor size in Krox20;Nf1 flox/− mice treated with sunitinib Age and sex matched Krox20;Nf1 flox/− mice (n=17) were treated with sunitinib malate at a dose of 60 mg/kg by daily oral gavage or a placebo control vehicle (n=9) as outlined in study schematic presented in Figure 2A . Mice tolerated treatment well with no apparent adverse effects. Both vehicle control and sunitinib treated mice exhibited weight loss during the first two weeks of treatment, likely due to physiologic effects of the daily oral gavages. Body weight was maintained thereafter within 10% of baseline through the remaining ten weeks of therapy, with no significant difference between the experimental and control cohorts. After 12 weeks of sunitinib therapy, mice were sacrificed to evaluate the extent of residual tumor burden. Dorsal root ganglia at each spinal level were dissected microscopically and the identification of all suspected plexiform neurofibromas was confirmed by histological analysis. We observed a significant reduction in the mean number of plexiform neurofibromas per animal in sunitinib-treated Krox20;Nf1 flox/− mice, with the sunitinib treatment group averaging 2.92 ± 0.51 tumors per mouse compared with 4.83 ± 0.72 tumors in the vehicle control treated cohort (p<0.05) ( Figure 2B ). Furthermore, mean tumor volume was reduced by 56% in the sunitinib treated mice as compared to the vehicle treated cohort over the same duration of therapy (p< 0.05) ( Figure 2C ).
Sunitinib therapy alters the plexiform neurofibroma microenvironment
Infiltrating Nf1 +/− mast cells and fibroblasts are abundant within the plexiform neurofibroma microenvironment and play a critical role in promoting tumor growth and progression [16, 17, 29] . Therefore, we tested whether sunitinib treatment altered the cellular microarchitecture of these tumors in vivo. Following 12 weeks of therapy, histological sectioning of dorsal root ganglia (DRG) and peripheral spinal nerves were compared between the treatment and placebo groups. H&E stained cross-sections from DRG and peripheral spinal nerves of Krox20;Nf1 flox/− mice treated with sunitinib demonstrate a marked decrease in tumor size, cellularity, and microarchitecture in representative plexiform neurofibromas compared to animals treated with the vehicle control ( Figure 3A, top panel) . Notably, Masson's Trichrome staining for collagen was diffuse and strongly positive throughout pNFs from the vehicle control cohort, while nearly absent in the sunitinib treated plexiforms ( Figure 3A , middle panel). Mast cells, though abundant within the PBS treated plexiforms ( Figure 3A , bottom panel), were dramatically reduced in number per high-power field (HPF) when enumerated in toluidine blue stained slides ( Figure 3B, p<0.05) . Finally, as shown in Figures 3C & D, there was a 4-fold increase in the number of apoptotic cells observed in the sunitinib treated group (p<0.01) compared to controls. Collectively, these observations provide evidence that sunitinib alters both the tumor size and cellular architecture of the tumor microenvironment in mice with pNF
Sunitinib treatment inhibits plexiform neurofibroma metabolic activity
In parallel experiments, small animal PET/CT imaging studies were performed to evaluate for changes in FDG uptake, which we have previously established as a biomarker of response to experimental therapy with imatinib in the Krox20;Nf1 flox/− GEMM [23] . Serial FDG-PET/CT imaging studies were performed at baseline prior to the initiation of therapy, and prior to euthanasia at the end of the study. All image data sets were transformed to standardized uptake value units (SUVs) and all voxel values above a threshold of SUV=1.0 within a three dimensional volume of interest along the spine were integrated to form an FDG biomarker index. As expected, placebo treated mice showed a marked increase in the FDG uptake both at baseline and the conclusion of the study. By contrast, sunitinib treated animals demonstrated a significant reduction in SUV uptake within the spinal cord and dorsal root ganglia at the end of the study ( Figure 4A and B) . Specifically, the SUV integral was reduced by nearly 70% in mice treated with sunitinib for 12 weeks of sunitinib therapy (p=0.03), compared to vehicle control mice which showed stable to mildly increased SUV integrals upon completion of the treatment course.
Discussion
Plexiform neurofibromas are complex nerve and soft tissue tumors which are pathognomonic of NF1, highly resistant to conventional chemotherapy, and associated with significant morbidity and mortality. To date, many promising therapies have failed to demonstrate efficacy in clinical trials [30] [31] [32] [33] , underscoring the importance of developing preclinical models which accurately recapitulate the biological complexity and growth kinetics of these neoplasms. Krox20;Nf1 flox/− mice develop diffuse enlargement of peripheral nerve roots along the dorsal spinal column closely reminiscent of human plexiform neurofibroma tissue both morphologically and histopathologically, which provides a preclinical animal model to test experimental therapeutics [23] .
Among the principle constituents of the plexiform neurofibroma microenvironment are infiltrating Nf1 +/− mast cells and fibroblasts which are abundant within these tumors [29] .
Mast cells are hematopoietic derived immune effector cells which are recruited to the microenvironment by aberrant SCF/c-Kit signaling and release a number of deleterious inflammatory mediators and trophic factors which potentiate pNF growth and progression [17] . Nf1 +/− fibroblasts, stimulated by a number of growth factors including PDGF, deposit collagen comprising greater than 50 percent of the tumor dry weight [34] . The role of Nf1 +/− vascular smooth muscle and endothelial cells to pNF initiation and progression is an understudied area of NF1 biology. Vascular smooth cell function is primarily controlled by PDGF receptor activation [35] and endothelial cell contribution to tumor neoangiogenesis is driven primarily by VEGF stimulation [36] . Previous studies demonstrate that both of these signaling axis are altered in both Nf1 +/− vascular smooth muscle cells [37] and in endothelial cells [38] . Finally, Nf1 −/− Schwann cells express many of these RTKs and secrete pathological concentrations of their respective ligands [39] [40] [41] [42] [43] which in part control multiple cell functions within the pNF.
Given the complexity of the tumor microenvironment in pNF, targeting multiple RTKs may be necessary in treating pNFs which is an emerging paradigm in tumor biology. Specifically, kinome analysis of both human and animals with different tumors suggest that inhibiting a single RTK can lead to activation of alternative signaling pathways that continue to drive tumorigenesis [44] [45] [46] [47] [48] . Furthermore, not all drugs inhibit the same target, such as c-kit, equivalently. Collectively, these observations provide rationale for testing a drug that inhibits multiple RTKs that are activated in pNF.
In comparison to imatinib mesylate which was used in a phase 2 clinical trial that resulted in tumor shrinkage in a subset of patients [49] , sunitinib possesses greater biochemical inhibition of c-kit activity [15] , a broader RTK profile [20] predicted to inhibit vascular smooth muscle, endothelium, and fibroblast function as well as established early phase safety data in pediatric patients [21] . Based on this rationale, we formally tested whether sunitinib would inhibit or reduce pNF progression in a previously established, genetically engineered murine model. Following 12 weeks of treatment, we observed a significant reduction in plexiform neurofibroma tumor burden (number and size) and metabolic activity as compared to vehicle treated controls. Historically, pNFs are slow growing tumors, even in our murine model, and response at 12 weeks has correlated well with tumor response clinically [23, 49] . Upon completion of the study, postmortem histological analysis demonstrated a marked decrease in infiltrating Nf1 +/− mast cells (by more than 50 percent) as well as dramatic reduction in fibroblast collagen deposition within the tumor microenvironment following sunitinib treatment. Additionally, TUNEL staining revealed an increase in apoptotic cells in sunitinib treated plexiform neurofibromas. These observations suggest that the biological effects of sunitinib treatment may relate not only to its ability to inhibit the recruitment and deranged functioning of Nf1 haploinsufficient mast cells and fibroblasts within the tumor microenvironment, but also to trigger programmed cell death within the tumors themselves.
FDG-PET was utilized as a biomarker in these studies. Though FDG-PET is not sufficiently sensitive in the human system to detect therapeutic effects of drugs on plexiform neurofibromas, we found that attenuation in FDG uptake on PET imaging correlated with biological response (tumor shrinkage, decreased proliferative index, etc.) to both imatinib [23] and sunitinib treatment in the preclinical pNF murine model. Three dimensional, volumetric MRI is the modality currently used in clinical protocols for experimental therapeutics. The challenge with volumetric MRI is that it is a static measure of tumor response. Though FDG-PET imaging is useful only as a preclinical tool for pNF, the development of novel PET tracers that can be utilized as a sensitive biomarker in patients is an area of great need moving forward.
The results of this study are further supported by recently published data involving a number of other complementary pharmacologic approaches. While not directly comparable due to different study designs, sunitinib demonstrated a similar reduction in tumor progression in mice as imatinib even though each drug targeted different RTKs. To test whether administering drugs which target different RTKs in combination will reduce tumors better than a single agent will require further detailed studies. These studies are currently underway given the potential therapeutic benefit.
In addition, several additional RTKs inhibitors have also been demonstrated to promote tumor regression in other spontaneous and xenograft derived pNF models. Sorafenib is a multi-RTK inhibitor with activity against c-Kit, PDGFR, and VEGFR although significantly less potent than sunitinib with respect to c-kit inhibition (IC 50 68 nM vs 10 nM for sunitinib). In the spontaneous Nf1 flox/flox ;DhhCre pNF murine model, sorafenib resulted in a modest reduction in tumor burden after eight weeks of treatment [50] . In contrast to the Krox20;Nf1 flox/− model, Nf1 flox/flox ;DhhCre mice exhibit robust biallelic inactivation of Nf1 in primitive glial precursor cells during early embryogenesis (~E12.5) with a recombination efficiency on the order of 30-50% [51] . The early and more widespread Nf1 recombination in the DhhCre model results in the development of diffuse, rapidly growing pNFs, thereby circumventing the requirement for an Nf1 haploinsufficient microenvironment in the genesis of these tumors which exists physiologically in human NF1 patients. Xenograft tumor models in athymic nude mice provide another preclinical context to evaluate the efficacy of candidate compounds, although the absence of a competent immune system limits their role in evaluating contributions of infiltrating mast cells and other inflammatory components of the pNF microenvironment which are known to play pivotal roles in tumor initiation and progression [17, 23] . Nonetheless, nilotinib, a tyrosine kinase inhibitor with activity towards Bcr-abl, DDR, PDGFR, and c-kit receptor kinases, also demonstrated tumor shrinkage in such a model [52] . Although the biological responses achieved in these studies are difficult to directly compare, evidence of reduced tumor burden in multiple preclinical models achieved by targeting a similar spectrum of RTKs provides strong impetus for advancement of these pharmacotherapies toward early phase clinical studies.
Aside from RTK inhibition, pharmacologic MEK inhibitors including PD0325901 and AZ6244 have also demonstrated promising results in preclinical [53] and early phase clinical studies (unpublished data). Taken together, these observations provide impetus for the rational design of combinatorial strategies simultaneously interfering with paracrine growth signals emanating from the pNF microenvironment while also targeting aberrant Raf/MEK/ERK pathway activation in tumorigenic Schwann cells. Advantages of such an approach might include opportunities to minimize adverse side effects by lowering the respective doses of each agent and the potential to overcome drug resistance mechanisms mediated through adaptive reprogramming of the kinome [44] [45] [46] [47] [48] .
In summary, preclinical testing of sunitinib in the Krox20;Nf1 flox/− GEMM demonstrated reduction in plexiform neurofibroma number and size, decreased mast cell infiltration, diminished fibroblast collagen deposition, and reduced metabolic activity (FDG PET uptake) of these tumors. This study provides important experimental insights for the design of clinical trials that target multiple RTKs that are active in pNFs and underscores the need to understand the contribution of distinct biochemical pathways to tumor progression and initiation. 
